Incyte Corporation
NASDAQ:INCYBiotechnology
-$0.77 today
- Market cap
- $24.01B
- Beta
- 0.79
- P/E (TTM)
- 13.7
- EPS (TTM)
- $7.18
Volume 1.21M
Average 1.58M
INCY Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Incyte CorporationNASDAQ: INCY
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income growth accelerates
Q2 FY2026 operating income of $697.9M rose 124.5% year over year, ahead of the +89.2% change in trailing-twelve-month operating income. Sequentially, it rose 115.3% from the prior quarter. Over 3 fiscal years it compounded at +31.4% a year.
Context
- Operating income amounted to 26.1% of revenue in FY2025, up 23.7 pp from a year earlier.
- Operating income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 17 analysts of $1.08B (-19.3%) for the fiscal year ending Dec 2026, a slowdown from the +1225.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $697.9M+115.3% QoQ
- Last fiscal yearDec 2025
- $1.34B+1225.6% YoY
- LTMJun 2026
- $1.84B+89.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- 1.34B USD
- Year-over-year change
- +1225.6%
- 4-year CAGR
- +23.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.34B | +1225.6% |
| FY2024 | 2024-12-31 | 101.29M | -84.5% |
| FY2023 | 2023-12-31 | 655.36M | +10.8% |
| FY2022 | 2022-12-31 | 591.63M | +1.0% |
| FY2021 | 2021-12-31 | 585.78M | — |
Operating Income vs competitors
How INCY compares with its peers on the latest reported figures
- INCY's LTM Jun 2026 operating income of $1.84B is the 2nd highest of the 11 companies compared; the peer median is $67.51M.
- Its year-over-year change of +89.2% is the 4th highest of 10, against a peer median of +3.4%.
- Operating income amounts to 31.6% of revenue for INCY, versus a peer median of 34.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.97B | +3.4% | -12.7% | 25.6% | |
| LTM Jun 2026 | $1.84B | +89.2% | +31.4% | 31.6% | |
| LTM Jun 2026 | $1.33B | — | -41.6% | 32.3% | |
| LTM Jul 2026 | $971.51M | +38.8% | +63.0% | 39.9% | |
| LTM Aug 2026 | $289.66M | +208.4% | — | 41.3% | |
| LTM Jun 2026 | $100.93M | +394.5% | +149.6% | 34.7% | |
| LTM Sep 2026 | $34.1M | +117.9% | — | 2.5% | |
| LTM Sep 2026 | -$39.45M | -46.4% | — | — | |
| LTM Mar 2026 | -$156.87M | -11.7% | — | — | |
| LTM Mar 2026 | -$170.85M | -30.3% | — | 344.6% | |
| LTM Mar 2026 | -$240.35M | -15.0% | — | — | |
| Peer median (excluding INCY) | $67.51M | +3.4% | +25.1% | 34.7% | |
Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.99B | 3.39B | 3.7B | 4.24B | 5.14B |
| Cost of Revenue | 150.99M | 207M | 254.99M | 312.1M | 372.1M |
| Gross Profit | 2.84B | 3.19B | 3.44B | 3.93B | 4.77B |
| Gross Margin | 94.9% | 93.9% | 93.1% | 92.6% | 92.8% |
| Research & Development | 1.46B | 1.59B | 1.63B | 2.61B | 2.05B |
| Selling, General & Admin | 739.56M | 1B | 1.16B | 1.22B | 1.38B |
| Operating Expenses | 2.25B | 2.6B | 2.79B | 3.83B | 3.43B |
| Depreciation & Amortization | 57.84M | 67.86M | 82.66M | 89.25M | 93.29M |
| EBITDA | 630.2M | 599.64M | 919.43M | 408.16M | 1.76B |
| EBITDA Margin | 21.1% | 17.7% | 24.9% | 9.6% | 34.2% |
| Operating Income | 585.78M | 591.63M | 655.36M | 101.29M | 1.34B |
| Operating Margin | 19.6% | 17.4% | 17.7% | 2.4% | 26.1% |
| Interest Income | 0 | 0 | 0 | 128.71M | 105.6M |
| Interest Expense | 1.91M | 2.67M | 2.55M | 2.28M | 2.43M |
| Other Income / Expenses | (15.33M) | (62.51M) | 178.86M | 215.34M | 321.66M |
| Income Before Tax | 570.44M | 529.12M | 834.22M | 316.63M | 1.66B |
| Pre-Tax Margin | 19.1% | 15.6% | 22.6% | 7.5% | 32.4% |
| Income Tax Expense | (378.14M) | 188.46M | 236.62M | 284.02M | 377.8M |
| Net Income | 948.58M | 340.66M | 597.6M | 32.62M | 1.29B |
| Net Margin | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% |
| EPS (Basic) | 4.30 | 1.53 | 2.67 | 0.16 | 6.59 |
| EPS (Diluted) | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 |
| Weighted Avg Shares | 220.43M | 222M | 223.63M | 207.11M | 195.2M |
| Weighted Avg Shares (Diluted) | 222.07M | 223.96M | 225.93M | 210.53M | 200.7M |
Incyte Corporation
NASDAQ:INCY
Intrinsic Alpha fair value
Locked
Current Price
$117.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.